SLC26A4: A Protein with Unique Structure and Function (G5172)

Target Name: SLC26A4

NCBI ID: G5172

SLC26A4

SLC26A4: A Protein with Unique Structure and Function

SLC26A4 (DFNB4) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the solute carrier family 26 (SLC26) and is responsible for transporting a variety of molecules across the cell membrane. One of the unique features of SLC26A4 is its ability to transport the drug propranolol across the membrane, making it an attractive drug target for researchers.

SLC26A4 has been shown to play a role in a variety of physiological processes in the body, including the regulation of pain, inflammation, and blood pressure. It is also involved in the development and maintenance of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This is important for maintaining the health and function of the brain, and is potentially relevant to a variety of neurological disorders.

One of the potential benefits of targeting SLC26A4 is its potential to treat a variety of conditions that are currently difficult to treat. For example, propranolol has been shown to be an effective treatment for both hypertension and anxiety disorders. By blocking the activity of SLC26A4, Researchers may be able to reduce the amount of propranolol that is absorbed into the brain and improve the effectiveness of the drug.

Another potential benefit of targeting SLC26A4 is its potential to be used as a biomarker. The ability of SLC26A4 to transport drugs across the membrane makes it an attractive target for researchers to study the effects of drugs on the brain. By measuring the activity of SLC26A4, researchers may be able to determine the effectiveness of a drug and identify potential side effects. This could be a valuable tool for the development of new treatments for a variety of neurological disorders.

In addition to its potential as a drug target and biomarker, SLC26A4 is also of interest to researchers because of its unique structure and function. SLC26A4 is a member of the SLC26 family, which is characterized by a conserved transmembrane domain and a unique cytoplasmic region. This structure allows SLC26A4 to be targeted by small molecules, which may be useful for studying its molecular mechanisms.

Overall, SLC26A4 is an interesting protein that has the potential to be a drug target and biomarker. Its unique structure and function make it a valuable tool for researchers to study the effects of drugs on the brain and develop new treatments for a variety of neurological disorders . Further research is needed to fully understand the role of SLC26A4 in physiological and pathological processes, and to develop new treatments based on its unique properties.

Protein Name: Solute Carrier Family 26 Member 4

Functions: Sodium-independent transporter of chloride and iodide (PubMed:10192399, PubMed:12107249, PubMed:11932316, PubMed:16684826, PubMed:24051746). Mediates electroneutral chloride-bicarbonate, chloride-iodide and chloride-formate exchange with 1:1 stoichiometry (PubMed:10644529, PubMed:15155570, PubMed:35601831, PubMed:24051746). Mediates electroneutral iodide-bicarbonate exchange (By similarity)

The "SLC26A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC26A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets